GSTP1

Summary

GSTP1 (glutathione S-transferase pi 1, HGNC:4638) is a protein-coding gene on chromosome 11q13.2, encoding Glutathione S-transferase P (P09211). Catalyzes conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. In precision oncology, GSTP1 I105V confers sensitivity to FOLFOX Regimen in Colorectal Cancer (CIViC Level B); 1 further curated variant–drug associations are listed below.

Glutathione S-transferases (GSTs) are a family of enzymes that play an important role in detoxification by catalyzing the conjugation of many hydrophobic and electrophilic compounds with reduced glutathione. Based on their biochemical, immunologic, and structural properties, the soluble GSTs are categorized into 4 main classes: alpha, mu, pi, and theta. This GST family member is a polymorphic gene encoding active, functionally different GSTP1 variant proteins that are thought to function in xenobiotic metabolism and play a role in susceptibility to cancer, and other diseases.

Source: NCBI Gene 2950 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 60 total — 1 likely-pathogenic
• Druggable target: yes — 2 molecules with ChEMBL bioactivity
• Precision-oncology evidence (CIViC): 2 curated variant–drug associations
• MANE Select transcript: NM_000852

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:4638
Approved symbol	GSTP1
Name	glutathione S-transferase pi 1
Location	11q13.2
Locus type	gene with protein product
Status	Approved
Aliases	GSTP
Ensembl gene	ENSG00000084207
Ensembl biotype	protein_coding
OMIM	134660
Entrez	2950

Gene structure

Transcript identifiers

Ensembl transcripts: 19 — 14 protein_coding, 3 retained_intron, 2 nonsense_mediated_decay

ENST00000398603, ENST00000398606, ENST00000467591, ENST00000489040, ENST00000494593, ENST00000495996, ENST00000498765, ENST00000646888, ENST00000906565, ENST00000906566, ENST00000906567, ENST00000914373, ENST00000914374, ENST00000914375, ENST00000914376, ENST00000914377, ENST00000914378, ENST00000914379, ENST00000914380

RefSeq mRNA: 1 — MANE Select: NM_000852 NM_000852

CCDS: CCDS41679

Canonical transcript exons

ENST00000398606 — 7 exons

Exon	Start	End
ENSE00001533853	67583812	67583844
ENSE00003491308	67584134	67584169
ENSE00003514541	67584464	67584570
ENSE00003556693	67585138	67585241
ENSE00003615072	67586104	67586211
ENSE00003750846	67584685	67584772
ENSE00003822108	67586389	67586653

Expression profiles

Bgee: expression breadth ubiquitous, 293 present calls, max score 99.83.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 432.1747 / max 6174.2938, expressed in 1718 samples.

FANTOM5 promoters (10 alternative TSS)

Promoter ID	TPM avg	Samples expressed
115490	415.6942	1717
115489	6.4303	1635
115495	2.5576	1073
115492	2.1212	1121
115488	1.8644	954
115494	0.9617	539
115486	0.8495	525
115491	0.7212	445
115487	0.6497	377
115493	0.3250	129

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lower esophagus mucosa	UBERON:0035834	99.83	gold quality
right uterine tube	UBERON:0001302	99.78	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	99.75	gold quality
metanephros cortex	UBERON:0010533	99.75	gold quality
right lobe of thyroid gland	UBERON:0001119	99.73	gold quality
left lobe of thyroid gland	UBERON:0001120	99.72	gold quality
esophagus mucosa	UBERON:0002469	99.70	gold quality
skin of abdomen	UBERON:0001416	99.65	gold quality
ectocervix	UBERON:0012249	99.65	gold quality
skin of leg	UBERON:0001511	99.63	gold quality
right lung	UBERON:0002167	99.60	gold quality
upper lobe of left lung	UBERON:0008952	99.59	gold quality
esophagus	UBERON:0001043	99.58	gold quality
ascending aorta	UBERON:0001496	99.56	gold quality
thoracic aorta	UBERON:0001515	99.56	gold quality
adenohypophysis	UBERON:0002196	99.56	gold quality
endocervix	UBERON:0000458	99.55	gold quality
gall bladder	UBERON:0002110	99.55	gold quality
descending thoracic aorta	UBERON:0002345	99.53	gold quality
stromal cell of endometrium	CL:0002255	99.52	gold quality
minor salivary gland	UBERON:0001830	99.51	gold quality
ventricular zone	UBERON:0003053	99.51	gold quality
body of stomach	UBERON:0001161	99.50	gold quality
left coronary artery	UBERON:0001626	99.49	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	99.49	gold quality
thyroid gland	UBERON:0002046	99.48	gold quality
mucosa of transverse colon	UBERON:0004991	99.48	gold quality
body of uterus	UBERON:0009853	99.48	gold quality
mucosa of stomach	UBERON:0001199	99.47	gold quality
granulocyte	CL:0000094	99.46	gold quality

Single-cell (SCXA)

Detected in 47 experiment(s), a significant marker in 33.

Experiment	Marker?	Max mean expression
E-MTAB-10855	yes	5430.96
E-HCAD-1	yes	4571.39
E-MTAB-6653	yes	3910.00
E-CURD-84	yes	3576.29
E-MTAB-6678	yes	2652.60
E-HCAD-5	yes	2211.51
E-MTAB-10042	yes	2113.35
E-HCAD-8	yes	2101.35
E-MTAB-5061	yes	1998.34
E-CURD-77	yes	1631.18
E-HCAD-4	yes	1463.01
E-GEOD-36552	yes	1440.11
E-GEOD-81547	yes	1240.61
E-MTAB-6075	yes	558.47
E-CURD-122	yes	54.11

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AP1, AR, CDX2, CEBPA, CEBPB, CEBPG, CREB1, CREM, CTNNBL1, DNMT1, ESR1, ESR2, EZH2, FOS, FOXC1, GATA1, IRF8, JUN, KAT6A, KLF10, KLF4, KLF5, KLF6, MAFK, MBD2, MYB, MYC, NFE2L2, NFIA, NFKB1, NFKB, PITX2, PPARA, RARB, RELA, SP1, SPI1, TBPL1, TP53, TP73

Literature-anchored findings (GeneRIF, showing 40)

• Genetic polymorphism of exon 5 of GSTP1 may be associated with COPD because the GSTP1/Ile105 genotype is predominantly found in COPD. It is suggested that the GSTP1/Ile105 genotype may be less protective against xenobiotics in tobacco smoke. (PMID:10413721)
• The acid denaturation of human glutathione transferase P1-1 has been performed to investigate the unfolding intermediates of the protein and their possible involvement in the refolding mechanism. (PMID:10856703)
• low level of expression seen in prostatic intraepithelial neoplasia and prostate adenocarcinoma, suggesting lack of detoxification activity that may be associated with carcinogenesis of the prostate (PMID:11550208)
• Expression in nasopharyngeal carcinoma (PMID:11727264)
• Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide. (PMID:11751372)
• Data suggest that GST-pi expression in tumor cells are related to drug resistance in epithelial ovarian cancer. (PMID:11783115)
• gene expression level of beta-TUB, Bcl-XL, and GSTpi was closely correlated with the IC50 for docetaxel (PMID:11788897)
• To determine the extent of promoter hypermethylation in early lung tumorigenesis, we analyzed promoter methylation status of the p16, death-associated protein kinase (DAPK) and glutathione S-transferase P1 (GSTP1) (PMID:11809677)
• Genetic determinants of lung cancer short-term survival: the role of glutathione-related genes (PMID:11844594)
• expression in malignant tissue and plasma levels in human colorectal and gastric tumors increased depending on tumor stage (PMID:11862479)
• The GSTP1 gene encodes the pi class glutathione S-transferase. (PMID:11912447)
• Glutathione S-transferase P1 and NADPH quinone oxidoreductase polymorphisms are associated with aberrant promoter methylation of P16(INK4a) and O(6)-methylguanine-DNA methyltransferase in sputum. (PMID:11956078)
• Methyl-CpG binding domain protein 2 represses transcription from hypermethylated pi-class glutathione S-transferase gene promoters in hepatocellular carcinoma cells (PMID:11960994)
• Glutathione S-transferase GSTP1 is a susceptibility gene for occupational asthma induced by isocyanates. Frequency of genotype lower in airway hyperresponsiveness to methacholine.(GSTP1) (PMID:11994713)
• polymophism related to chronic lymphocytic leukemia (PMID:12010828)
• The GSTP1 gene encodes for an enzyme, glutathione S-transferase pi (GSTpi),involved in detoxification of carcinogens. An aminoacid substitution (I105V) in GSTP1 produces a variant enzyme with lower activity and less capability of effective detoxification. (PMID:12010858)
• Association beetween polymorphism and survival in colorectal cancer (PMID:12072547)
• Etoposide treatment was able to induce GST P1-1 polymerization and activation of apoptosis (PMID:12112003)
• GSTpi expression is a possible mechanism by which esophageal adenocarcinoma cells can protect themselves against the cytotoxic or antiproliferative effects of free radicals in the tumor microenvironment (PMID:12112555)
• that lipid peroxidation in the bile ducts with reduced expression of glutathione-S-transferase-pi, may be an important pathologic process leading to the bile duct damage of primary biliary cirrhosis. (PMID:12127421)
• Interindividual variation and organ-specific patterns of glutathione S-transferase ,GSTP1, GSTA1, and GSTA2 were major components (PMID:12139976)
• The polymorphism of GSTP1 gene is linked to a genetic susceptibility to COPD. (PMID:12172904)
• The deficient genotypes for GSTM1 and GSTP1 seem thus to be important risk modifiers for lung cancer, especially in combination. (PMID:12189190)
• GSTP1 is transcriptionally regulated by cAMP- and CREB-1 in human tumor cells (PMID:12210727)
• Liver disease in pediatric patients with cystic fibrosis is associated with glutathione S-transferase P1 polymorphism. (PMID:12297838)
• Variants of this gene confer differential cytoprotection against anticancer agents in E coli. (PMID:12360105)
• Associations between carcinogen0-DNA damage, enzyme genotype and risk of lung cancer (PMID:12376472)
• Contribution of glycine 146 to a conserved folding module affecting stability and refolding of human glutathione transferase p1-1. (PMID:12414796)
• role in susceptibility to childhood acute lymphoblastic leukemia (PMID:12439226)
• Does not increase in transformed keratinocytes and melanocytes in culture. No increase in GSTP1-1 observed after treatment with antioxidant response element-mediated inducers. Effect of c-Ha-ras on GSTP1-1 expression in HaCaT cells appears limited. (PMID:12443843)
• Methyl-CpG-binding domain protein-2 mediates transcriptional repression associated with hypermethylated GSTP1 CpG islands in MCF-7 breast cancer cells. (PMID:12543808)
• HBV infection may increase expression of PCNA and GST-pi. (PMID:12632497)
• Genotype and allele distributions of GSTP1 polymorphism in patients with schizophrenia are not significantly different from those of the controls, suggesting GSTP1 polymorphism may not confer susceptibility to schizophrenia in the Korean population. (PMID:12691788)
• that prostate cancer cells induce an injury response in the stroma during progression to hormone independence, which results in GST pi expression. (PMID:12746833)
• MRP, GST-pi, topo IIalpha,and LRP play important roles in the primary MDR of gastric carcinoma. The expression of them are associated with the differentiation, but are not associated with the invasion degree and lymph node metastasis. (PMID:12753710)
• In this study, we have used quantitative PCR to analyse expression of beta-tubulin III, stathmin, RRM1, COX-2 and GSTP1 in mRNA isolated from paraffin-embedded tumor biopsies of 75 nonsmall-cell lung cancer patients treated as part of a randomized trial (PMID:12789263)
• patients with the less stable variant have a decreased ability to detoxify chemotherapeutic substrates, including melphalan, and have an altered outcome following treatment for multiple myeloma. (PMID:12791655)
• There was no association between GSTT1 or GSTP1 genotype and survival in the overall study population, nor in a subgroup of patients treated with chemotherapy. (PMID:12814998)
• we found Phe151Leu substitution in an African-American subject (1 out of 111). Analysis of the three-dimensional structure showed that substitution of Phe 151 with Leu produces a hydrophobic cavity in the GSTP1 core, thereby destabilizing its structure (PMID:12818186)
• There are no associations between the genotypes and the risk of developing acute leukemia. (PMID:12827651)

Cross-species orthologs

40 orthologs

Organism	Symbol	Gene ID
mus_musculus	Gstp2	ENSMUSG00000038155
mus_musculus	Gstp1	ENSMUSG00000060803
rattus_norvegicus	Gstp1	ENSRNOG00000018237
caenorhabditis_elegans		WBGENE00001750
caenorhabditis_elegans		WBGENE00001751
caenorhabditis_elegans		WBGENE00001752
caenorhabditis_elegans		WBGENE00001753
caenorhabditis_elegans		WBGENE00001754
caenorhabditis_elegans		WBGENE00001755
caenorhabditis_elegans		WBGENE00001756
caenorhabditis_elegans		WBGENE00001757
caenorhabditis_elegans		WBGENE00001758
caenorhabditis_elegans		WBGENE00001759
caenorhabditis_elegans		WBGENE00001760
caenorhabditis_elegans		WBGENE00001761
caenorhabditis_elegans		WBGENE00001762
caenorhabditis_elegans		WBGENE00001764
caenorhabditis_elegans		WBGENE00001765
caenorhabditis_elegans		WBGENE00001766
caenorhabditis_elegans		WBGENE00001767
caenorhabditis_elegans		WBGENE00001769
caenorhabditis_elegans		WBGENE00001770
caenorhabditis_elegans		WBGENE00001772
caenorhabditis_elegans		WBGENE00001774
caenorhabditis_elegans		WBGENE00001775
caenorhabditis_elegans		WBGENE00001776
caenorhabditis_elegans		WBGENE00001777
caenorhabditis_elegans		WBGENE00001779
caenorhabditis_elegans		WBGENE00001780
caenorhabditis_elegans		WBGENE00001781
caenorhabditis_elegans		WBGENE00001782
caenorhabditis_elegans		WBGENE00001783
caenorhabditis_elegans		WBGENE00001785
caenorhabditis_elegans		WBGENE00001786
caenorhabditis_elegans		WBGENE00001787
caenorhabditis_elegans		WBGENE00001789
caenorhabditis_elegans		WBGENE00018911
caenorhabditis_elegans		WBGENE00018912
caenorhabditis_elegans	W10C8.4	WBGENE00021127
caenorhabditis_elegans		WBGENE00021566

Paralogs (11): GSTM1 (ENSG00000134184), GSTM5 (ENSG00000134201), GSTM3 (ENSG00000134202), HPGDS (ENSG00000163106), GSTM4 (ENSG00000168765), GSTA4 (ENSG00000170899), GSTA3 (ENSG00000174156), GSTA5 (ENSG00000182793), GSTM2 (ENSG00000213366), GSTA1 (ENSG00000243955), GSTA2 (ENSG00000244067)

Protein

Protein identifiers

Glutathione S-transferase P — P09211 (reviewed: P09211)

Alternative names: GST class-pi, GSTP1-1

All UniProt accessions (6): P09211, A0A087X243, A0A087X2E9, A0A2R8Y5E5, A8MX94, V9HWE9

UniProt curated annotations — full annotation on UniProt →

Function. Catalyzes conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Involved in the formation of glutathione conjugates of both prostaglandin A2 (PGA2) and prostaglandin J2 (PGJ2). Participates in the formation of novel hepoxilin regioisomers. Acts as a negative regulator of ferroptosis by mediating glutathione conjugation and detoxification of 4-hydroxynonenal (4-HNE) reactive aldehyde. Negatively regulates CDK5 activity via p25/p35 translocation to prevent neurodegeneration.

Subunit / interactions. Homodimer. Interacts with CDK5.

Subcellular location. Cytoplasm. Mitochondrion. Nucleus.

Post-translational modifications. Ubiquitinated at Lys-55, Lys-121 and Lys-191 by SMURF2, leading to its degradation and initiation of ferroptosis.

Similarity. Belongs to the GST superfamily. Pi family.

RefSeq proteins (1): NP_000843* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003082	GST_pi	Family
IPR004045	Glutathione_S-Trfase_N	Domain
IPR004046	GST_C	Domain
IPR010987	Glutathione-S-Trfase_C-like	Domain
IPR036249	Thioredoxin-like_sf	Homologous_superfamily
IPR036282	Glutathione-S-Trfase_C_sf	Homologous_superfamily
IPR040079	Glutathione_S-Trfase	Family
IPR050213	GST_superfamily	Family

Pfam: PF02798, PF14497

Enzyme classification (BRENDA):

• EC 2.5.1.18 — glutathione transferase (BRENDA: 178 organisms, 548 substrates, 680 inhibitors, 878 Km, 525 kcat entries)

Substrate kinetics (BRENDA)

79 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
1-CHLORO-2,4-DINITROBENZENE	0.0003–223.6	289
GLUTATHIONE	0.0002–532.43	253
GSH	0.0003–37.4	62
REDUCED GLUTATHIONE	0.017–11.4	24
ETHACRYNIC ACID	0.0001–2.43	19
CUMENE HYDROPEROXIDE	0.038–14.3	10
(+)-2-BROMO-3-(4-NITROPHENYL)PROPANOIC ACID	0.023–0.417	8
MONOCHLOROBIMANE	0.004–0.25	8
4-CHLORO-7-NITROBENZO-2-OXA-1,3-DIAZOLE	0.324–3.866	7
1-IODOHEXANE	0.009–0.059	6
ALACHLOR	0.042–7.23	6
PHENETHYL ISOTHIOCYANATE	0.0065–0.14	6
STYRENE 7,8-OXIDE	0.064–0.365	6
1,2-DICHLORO-4-NITROBENZENE	0.27–1.4	5
1-CHLORO-2,3-DINITROBENZOATE	0.21–20.7	5

Catalyzed reactions (Rhea), 6 shown:

• RX + glutathione = an S-substituted glutathione + a halide anion + H(+) (RHEA:16437)
• 11(S)-hydroxy-14(S),15(S)-epoxy-(5Z,8Z,12E)-eicosatrienoate + glutathione = (11S,15S)-dihydroxy-14(R)-S-glutathionyl-(5Z,8Z,12E)-eicosatrienoate (RHEA:50260)
• prostaglandin A2 + glutathione = prostaglandin A2-S-(S)-glutathione (RHEA:50800)
• prostaglandin J2 + glutathione = prostaglandin J2-S-(R)-glutathione (RHEA:50804)
• prostaglandin J2 + glutathione = prostaglandin J2-S-(S)-glutathione (RHEA:50808)
• (E)-4-hydroxynon-2-enal + glutathione = 3-(glutathion-S-yl)-4-hydroxynonanal (RHEA:85343)

UniProt features (52 total): helix 13, mutagenesis site 8, strand 8, modified residue 6, binding site 6, cross-link 3, sequence variant 3, domain 2, initiator methionine 1, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

68 structures, top 30 by resolution.

PDB	Method	Resolution (Å)
5J41	X-RAY DIFFRACTION	1.19
2A2R	X-RAY DIFFRACTION	1.4
6Y1E	X-RAY DIFFRACTION	1.4
5DAL	X-RAY DIFFRACTION	1.5
3GUS	X-RAY DIFFRACTION	1.53
3CSH	X-RAY DIFFRACTION	1.55
6AP9	X-RAY DIFFRACTION	1.55
6LLX	X-RAY DIFFRACTION	1.58
3DGQ	X-RAY DIFFRACTION	1.6
2A2S	X-RAY DIFFRACTION	1.7
7BIA	X-RAY DIFFRACTION	1.73
1AQW	X-RAY DIFFRACTION	1.8
1PGT	X-RAY DIFFRACTION	1.8
3HKR	X-RAY DIFFRACTION	1.8
3IE3	X-RAY DIFFRACTION	1.8
3KMN	X-RAY DIFFRACTION	1.8
5DJL	X-RAY DIFFRACTION	1.8
3N9J	X-RAY DIFFRACTION	1.85
1LBK	X-RAY DIFFRACTION	1.86
13GS	X-RAY DIFFRACTION	1.9
16GS	X-RAY DIFFRACTION	1.9
17GS	X-RAY DIFFRACTION	1.9
18GS	X-RAY DIFFRACTION	1.9
19GS	X-RAY DIFFRACTION	1.9
22GS	X-RAY DIFFRACTION	1.9
2GSS	X-RAY DIFFRACTION	1.9
2PGT	X-RAY DIFFRACTION	1.9
3CSI	X-RAY DIFFRACTION	1.9
3CSJ	X-RAY DIFFRACTION	1.9
3GSS	X-RAY DIFFRACTION	1.9

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P09211-F1	98.05	0.99

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (6): 8; 14; 39; 45; 52–53; 65–66

Post-translational modifications (9): 4, 62, 103, 116, 128, 199, 55, 121, 191

Mutagenesis-validated functional residues (8):

Position	Phenotype
8	reduces catalytic activity about 50-fold.
52–53	impaired ability to inhibit ferroptosis.
55	decreased ubiquitination. in 3r; abolished ubiquitination, preventing its degradation; when associated with r-121 and r-
99	reduces affinity for glutathione. slightly reduced catalytic activity.
105	impaired ability to inhibit ferroptosis.
109	impaired ability to inhibit ferroptosis.
121	decreased ubiquitination. in 3r; abolished ubiquitination, preventing its degradation; when associated with r-55 and r-1
191	strongly decreased ubiquitination. in 3r; abolished ubiquitination, preventing its degradation; when associated with r-5

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-156590	Glutathione conjugation
R-HSA-3299685	Detoxification of Reactive Oxygen Species
R-HSA-6798695	Neutrophil degranulation
R-HSA-9753281	Paracetamol ADME

MSigDB gene sets: 439 (showing top): GSE18804_BRAIN_VS_COLON_TUMORAL_MACROPHAGE_DN, GSE45365_CTRL_VS_MCMV_INFECTION_NK_CELL_DN, GOBP_NEGATIVE_REGULATION_OF_ERK1_AND_ERK2_CASCADE, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_REGULATION_OF_LEUKOCYTE_PROLIFERATION, AP1_01, GOBP_RESPONSE_TO_ETHANOL, HONMA_DOCETAXEL_RESISTANCE, REACTOME_BIOLOGICAL_OXIDATIONS, REACTOME_INNATE_IMMUNE_SYSTEM, WWTAAGGC_UNKNOWN, GOBP_NEGATIVE_REGULATION_OF_SMOOTH_MUSCLE_CELL_PROLIFERATION, GOBP_RESPONSE_TO_ESTRADIOL, GOBP_CELL_CHEMOTAXIS, GOBP_NEGATIVE_REGULATION_OF_INTERLEUKIN_1_PRODUCTION

GO Biological Process (46): negative regulation of transcription by RNA polymerase II (GO:0000122), response to reactive oxygen species (GO:0000302), negative regulation of acute inflammatory response (GO:0002674), prostaglandin metabolic process (GO:0006693), glutathione metabolic process (GO:0006749), xenobiotic metabolic process (GO:0006805), central nervous system development (GO:0007417), negative regulation of tumor necrosis factor-mediated signaling pathway (GO:0010804), oligodendrocyte development (GO:0014003), animal organ regeneration (GO:0031100), response to estradiol (GO:0032355), negative regulation of interleukin-1 beta production (GO:0032691), negative regulation of tumor necrosis factor production (GO:0032720), cellular response to insulin stimulus (GO:0032869), regulation of stress-activated MAPK cascade (GO:0032872), negative regulation of stress-activated MAPK cascade (GO:0032873), positive regulation of superoxide anion generation (GO:0032930), response to L-ascorbic acid (GO:0033591), common myeloid progenitor cell proliferation (GO:0035726), nitric oxide storage (GO:0035732), negative regulation of apoptotic process (GO:0043066), negative regulation of canonical NF-kappaB signal transduction (GO:0043124), response to amino acid (GO:0043200), negative regulation of MAPK cascade (GO:0043409), linoleic acid metabolic process (GO:0043651), response to ethanol (GO:0045471), negative regulation of JNK cascade (GO:0046329), negative regulation of fibroblast proliferation (GO:0048147), hepoxilin biosynthetic process (GO:0051122), regulation of ERK1 and ERK2 cascade (GO:0070372), negative regulation of ERK1 and ERK2 cascade (GO:0070373), negative regulation of leukocyte proliferation (GO:0070664), cellular response to lipopolysaccharide (GO:0071222), cellular response to epidermal growth factor stimulus (GO:0071364), cellular response to glucocorticoid stimulus (GO:0071385), cellular response to cell-matrix adhesion (GO:0071460), negative regulation of monocyte chemotactic protein-1 production (GO:0071638), negative regulation of smooth muscle cell chemotaxis (GO:0071672), negative regulation of ferroptosis (GO:0110076), glutathione derivative biosynthetic process (GO:1901687)

GO Molecular Function (12): glutathione transferase activity (GO:0004364), glutathione peroxidase activity (GO:0004602), fatty acid binding (GO:0005504), JUN kinase binding (GO:0008432), toxic substance binding (GO:0015643), protein serine/threonine kinase inhibitor activity (GO:0030291), S-nitrosoglutathione binding (GO:0035730), dinitrosyl-iron complex binding (GO:0035731), nitric oxide binding (GO:0070026), protein binding (GO:0005515), transferase activity (GO:0016740), protein kinase binding (GO:0019901)

GO Cellular Component (11): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615), nucleus (GO:0005634), cytoplasm (GO:0005737), mitochondrion (GO:0005739), cytosol (GO:0005829), vesicle (GO:0031982), secretory granule lumen (GO:0034774), extracellular exosome (GO:0070062), TRAF2-GSTP1 complex (GO:0097057), ficolin-1-rich granule lumen (GO:1904813)

Reactome top-level categories

Rollup of top-4 pathways:

Category	Pathways
Phase II - Conjugation of compounds	1
Cellular response to chemical stress	1
Innate Immune System	1
Drug ADME	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
response to oxygen-containing compound	2
stress-activated MAPK cascade	2
binding	2
intracellular membrane-bounded organelle	2
cytoplasm	2
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
negative regulation of DNA-templated transcription	1
response to oxidative stress	1
acute inflammatory response	1
regulation of acute inflammatory response	1
negative regulation of inflammatory response	1
prostanoid metabolic process	1
modified amino acid metabolic process	1
sulfur compound metabolic process	1
metabolic process	1
cellular response to xenobiotic stimulus	1
nervous system development	1
system development	1
negative regulation of cytokine-mediated signaling pathway	1
regulation of tumor necrosis factor-mediated signaling pathway	1
tumor necrosis factor-mediated signaling pathway	1
glial cell development	1
oligodendrocyte differentiation	1
regeneration	1
animal organ development	1
response to lipid	1
interleukin-1 beta production	1
regulation of interleukin-1 beta production	1
negative regulation of interleukin-1 production	1
tumor necrosis factor production	1
regulation of tumor necrosis factor production	1
negative regulation of tumor necrosis factor superfamily cytokine production	1
response to insulin	1
cellular response to peptide hormone stimulus	1
regulation of MAPK cascade	1
regulation of stress-activated protein kinase signaling cascade	1
regulation of stress-activated MAPK cascade	1
negative regulation of MAPK cascade	1

Protein interactions and networks

STRING

3058 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GSTP1	JUN	P05412	920
GSTP1	EPHX1	P07099	894
GSTP1	GSTZ1	O43708	890
GSTP1	SLCO6A1	Q86UG4	880
GSTP1	MAPK8	P45983	875
GSTP1	FANCC	Q00597	811
GSTP1	RASSF1	Q9NS23	811
GSTP1	GSTT2B	P0CG30	791
GSTP1	GSTO2	Q9H4Y5	786
GSTP1	CYP2E1	P05181	784
GSTP1	CYP3A4	P05184	750
GSTP1	GSTK1	Q9Y2Q3	749
GSTP1	CYP1A1	P04798	736
GSTP1	MTHFR	P42898	725
GSTP1	CYP1B1	Q16678	722

IntAct

198 interactions, top by confidence:

A	B	Type	Score
GSTP1	KRTAP10-7	psi-mi:“MI:0915”(physical association)	0.720
KRT31	GSTP1	psi-mi:“MI:0915”(physical association)	0.720
APPBP2	GSTP1	psi-mi:“MI:0915”(physical association)	0.720
KRTAP10-7	GSTP1	psi-mi:“MI:0915”(physical association)	0.720
GSTP1	APPBP2	psi-mi:“MI:0915”(physical association)	0.720
GSTP1	KRT31	psi-mi:“MI:0915”(physical association)	0.720
JADE1	KAT7	psi-mi:“MI:0914”(association)	0.720
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
TRAF2	GSTP1	psi-mi:“MI:2364”(proximity)	0.680
TRAF2	GSTP1	psi-mi:“MI:0915”(physical association)	0.680
	GSTP1	psi-mi:“MI:0915”(physical association)	0.560
GSTP1	KRTAP10-9	psi-mi:“MI:0915”(physical association)	0.560
GSTP1	NOTCH2NLA	psi-mi:“MI:0915”(physical association)	0.560
GSTP1		psi-mi:“MI:0915”(physical association)	0.560

BioGRID (265): GSTP1 (Affinity Capture-MS), KRT31 (Two-hybrid), APPBP2 (Two-hybrid), KRTAP10-7 (Two-hybrid), KRTAP10-9 (Two-hybrid), KRTAP10-3 (Two-hybrid), NOTCH2NL (Two-hybrid), GSTP1 (Reconstituted Complex), GSTP1 (Co-localization), GSTP1 (Affinity Capture-MS), GSTP1 (Affinity Capture-MS), GSTP1 (Affinity Capture-MS), GSTP1 (Co-fractionation), GSTP1 (Co-fractionation), ACY1 (Affinity Capture-MS)

ESM2 similar proteins: A2VE14, B2GV54, O43324, O43488, O95154, P04906, P09211, P19157, P20135, P28801, P46424, P46425, P47802, P47954, P80031, P80147, P80404, P82197, Q0II59, Q0VD27, Q27HK4, Q28514, Q3U129, Q4R3I0, Q5NVN7, Q5PPH0, Q5R8R5, Q5REA8, Q5RKN4, Q60550, Q67FW5, Q6AXQ0, Q6GV29, Q6UWP2, Q8BGB7, Q8BK26, Q8NHP1, Q96MZ0, Q9BGI0, Q9BRA2

Diamond homologs: O15217, O18879, O73888, P00502, P04903, P04904, P04906, P08263, P09210, P09211, P10648, P13745, P14942, P19157, P24472, P26624, P26697, P30115, P35661, P46088, P46418, P46424, P46425, P47954, P51781, P80031, P80894, P81706, P81942, Q08392, Q08393, Q08862, Q08863, Q16772, Q28035, Q28514, Q54YN2, Q556G3, Q5E9G0, Q5R8R5

SIGNOR signaling

17 interactions.

A	Effect	B	Mechanism
EGFR	up-regulates	GSTP1	phosphorylation
FBXO8	“down-regulates quantity by destabilization”	GSTP1	binding
“Cullin 1-RBX1-Skp1”	“down-regulates quantity by destabilization”	GSTP1	polyubiquitination
PRKCH	“up-regulates activity”	GSTP1	phosphorylation
PRKCZ	“up-regulates activity”	GSTP1	phosphorylation
PRKCG	“up-regulates activity”	GSTP1	phosphorylation
PRKCE	“up-regulates activity”	GSTP1	phosphorylation
PRKCB	“up-regulates activity”	GSTP1	phosphorylation
PRKCA	“up-regulates activity”	GSTP1	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 131 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Dengue Virus Genome Translation and Replication	5	16.5×	1e-03
Toll Like Receptor 3 (TLR3) Cascade	5	10.1×	6e-03
TRIF (TICAM1)-mediated TLR4 signaling	5	9.9×	6e-03
MyD88-independent TLR4 cascade	5	9.6×	6e-03
Signaling by ALK fusions and activated point mutants	6	9.4×	3e-03
Toll Like Receptor TLR6:TLR2 Cascade	5	9.2×	7e-03
Toll Like Receptor 2 (TLR2) Cascade	5	9.0×	7e-03
Apoptosis	5	8.8×	7e-03

GO biological processes:

GO term	Partners	Fold	FDR
autophagosome maturation	6	18.6×	5e-04
mitophagy	6	16.9×	6e-04
JNK cascade	6	14.4×	1e-03
autophagosome assembly	6	11.9×	2e-03

Disease & clinical

Cancer significance

Clinical variants and AI predictions

ClinVar

60 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	19
Likely benign	1
Benign	20

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
496691	NM_000852.4(GSTP1):c.336+79_336+80delinsCA	Likely pathogenic

SpliceAI

963 predictions. Top by Δscore:

Variant	Effect	Δscore
11:67583843:CA:C	donor_gain	1.0000
11:67583845:G:GG	donor_gain	1.0000
11:67583849:G:GG	donor_gain	1.0000
11:67584459:CGCA:C	acceptor_loss	1.0000
11:67584460:GCAG:G	acceptor_loss	1.0000
11:67584461:CAGGC:C	acceptor_loss	1.0000
11:67584462:A:AG	acceptor_gain	1.0000
11:67584462:A:C	acceptor_loss	1.0000
11:67584462:AG:A	acceptor_gain	1.0000
11:67584462:AGGCC:A	acceptor_gain	1.0000
11:67584463:G:A	acceptor_loss	1.0000
11:67584463:G:GT	acceptor_gain	1.0000
11:67584463:GG:G	acceptor_gain	1.0000
11:67584463:GGC:G	acceptor_gain	1.0000
11:67584463:GGCC:G	acceptor_gain	1.0000
11:67584463:GGCCG:G	acceptor_gain	1.0000
11:67584547:G:GT	donor_gain	1.0000
11:67584566:CCTGC:C	donor_gain	1.0000
11:67584567:CTGC:C	donor_gain	1.0000
11:67584568:TGC:T	donor_gain	1.0000
11:67584568:TGCGT:T	donor_loss	1.0000
11:67584569:GC:G	donor_gain	1.0000
11:67584569:GCG:G	donor_gain	1.0000
11:67584571:G:GG	donor_gain	1.0000
11:67584571:GTAA:G	donor_loss	1.0000
11:67584572:T:G	donor_loss	1.0000
11:67584682:CAGCT:C	acceptor_loss	1.0000
11:67584683:A:AG	acceptor_gain	1.0000
11:67584683:AGC:A	acceptor_loss	1.0000
11:67584684:G:GG	acceptor_gain	1.0000

AlphaMissense

1342 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:67584157:T:C	F9L	0.989
11:67584159:C:A	F9L	0.989
11:67584159:C:G	F9L	0.989
11:67584751:C:A	R71S	0.989
11:67584707:T:C	F56S	0.985
11:67586194:T:C	F143L	0.985
11:67586196:C:A	F143L	0.985
11:67586196:C:G	F143L	0.985
11:67584761:G:A	G74D	0.984
11:67584543:G:C	W39C	0.983
11:67584543:G:T	W39C	0.983
11:67584752:G:C	R71P	0.983
11:67584481:C:A	R19S	0.979
11:67584760:G:C	G74R	0.979
11:67584154:T:C	Y8H	0.978
11:67584764:G:C	R75P	0.977
11:67585176:G:C	D91H	0.977
11:67584464:G:T	G13V	0.976
11:67584700:C:T	P54S	0.975
11:67584701:C:A	P54H	0.974
11:67584735:G:C	Q65H	0.974
11:67584735:G:T	Q65H	0.974
11:67585177:A:T	D91V	0.974
11:67584541:T:A	W39R	0.973
11:67584541:T:C	W39R	0.973
11:67586399:C:A	A152D	0.973
11:67584169:G:C	G13R	0.972
11:67586411:T:C	L156P	0.972
11:67584466:C:A	R14S	0.971
11:67586401:G:C	D153H	0.971

dbSNP variants (sampled 300 via entrez): RS1000411337 (11:67582233 C>T), RS1000615502 (11:67582409 G>A), RS1001448524 (11:67586322 G>C,T), RS1001516756 (11:67582500 C>T), RS1001736094 (11:67583028 C>G), RS1002447434 (11:67586825 A>AAC), RS1003198398 (11:67583921 C>T), RS1003200791 (11:67583015 T>C,G), RS1003273677 (11:67584247 T>A), RS1004461012 (11:67584398 C>T), RS1005204809 (11:67584386 C>A,T), RS1005325649 (11:67585920 G>A), RS1006281274 (11:67583094 G>A,C), RS1006607124 (11:67585015 A>G,T), RS1007216260 (11:67585024 TC>T)

Disease associations

OMIM: gene MIM:134660 | disease phenotypes: MIM:611381

GenCC curated gene-disease

Mondo (2): pulmonary disease, chronic obstructive, susceptibility to (MONDO:0100167), susceptibility to visceral leishmaniasis, 2 (MONDO:0012660)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST010002_241	Refractive error	3.000000e-13
GCST012227_671	Hip circumference adjusted for BMI	7.000000e-17
GCST90020024_401	A body shape index	9.000000e-11
GCST90020029_347	Waist circumference adjusted for body mass index	1.000000e-08

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0008039	BMI-adjusted hip circumference
EFO:0007789	BMI-adjusted waist circumference

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3902 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

2 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 43,152 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL456	ETHACRYNIC ACID	4	20,004
CHEMBL6246	ELLAGIC ACID	2	23,148

Clinical evidence (CIViC)

Drug × variant × indication: 2 predictive associations from 2 curated evidence items.

Variant	Therapy	Indication	Effect	Level	CIViC
GSTP1 I105V	FOLFOX Regimen	Colorectal Cancer	Sensitivity/Response	CIViC B	EID670
GSTP1 Deletion	Carboplatin + Paclitaxel + Cisplatin	Ovarian Carcinoma	Sensitivity/Response	CIViC D	EID660

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

22 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs1138272	Efficacy	3	cisplatin	Neoplasms
rs1138272	Metabolism/PK	3	thiotepa	Neoplasms
rs1695	Efficacy	3	cisplatin;cyclophosphamide	Ovarian Neoplasms
rs1695	Toxicity	3	Platinum compounds	Neoplasms
rs1695	Toxicity	3	cyclophosphamide;epirubicin	Breast Neoplasms;Drug Toxicity
rs1695	Toxicity	3	cyclophosphamide;epirubicin	Breast Neoplasms;Neutropenia
rs1695	Efficacy	3	capecitabine;epirubicin;platinum	Colorectal Neoplasms
rs1695	Efficacy	3	cyclophosphamide;epirubicin	Breast Neoplasms
rs1695	Efficacy	3	cisplatin;doxorubicin;methotrexate	Osteosarcoma
rs1695	Toxicity	3	cisplatin;doxorubicin;methotrexate	Cardiotoxicity;Osteosarcoma
rs1695	Toxicity	3	doxorubicin	Leukopenia;Osteosarcoma
rs1695	Toxicity	3	mercaptopurine;methotrexate	Acute lymphoblastic leukemia;Drug Toxicity
rs1695	Toxicity	3	fluorouracil	Rectal Neoplasms
rs1695	Efficacy	3	dimethyl fumarate	Psoriasis
rs1695	Efficacy	4	oxaliplatin
rs1695	Efficacy	3	Platinum compounds	Neoplasms
rs1695	Toxicity	3	isoniazid;rifampin	Drug-induced liver injury;Tuberculosis
rs1695	Toxicity	3	cyclophosphamide;doxorubicin;fluorouracil	Breast Neoplasms
rs1695	Toxicity	3	bleomycin;cisplatin;etoposide	Infectious disease;Nausea;Testicular Neoplasms
rs1695	Toxicity	3	cisplatin;oxaliplatin;Platinum compounds	Colorectal Neoplasms;Gastrointestinal Neoplasms;Non-Small Cell Lung Carcinoma;Ovarian Neoplasms
rs1695	Toxicity	3	cisplatin	Medulloblastoma;Neoplasms;Ototoxicity;Testicular Neoplasms
rs1695	Efficacy	3	cyclophosphamide	Neoplasms

PharmGKB variants

4 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs1695	GSTP1	3	7.75	20	fluorouracil;doxorubicin;cyclophosphamide;epirubicin;capecitabine;epirubicin;platinum;cyclophosphamide;doxorubicin;fluorouracil;bleomycin;cisplatin;etoposide;cisplatin;oxaliplatin;Platinum compounds;Platinum compounds;cisplatin;cyclophosphamide;oxaliplatin
rs1138272	GSTP1	3	1.50	2	thiotepa;cisplatin
rs7952081	GSTP1		0.00	0
rs4147581	GSTP1		0.00	0

Binding affinities (BindingDB)

611 measured of 953 human assays (956 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-[(6,7-difluoro-1H-indol-5-yl)oxy]-N-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)sulfonyl]benzamide	KI	0.039 nM	US-9493431: Apoptosis-inducing agent for the treatment of cancer and immune and autoimmune diseases
4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)sulfonyl]-2-[(6-fluoro-1H-indol-5-yl)oxy]benzamide	KI	0.053 nM	US-9493431: Apoptosis-inducing agent for the treatment of cancer and immune and autoimmune diseases
4-[4-[[2-(4-chlorophenyl)cyclohexen-1-yl]methyl]piperazin-1-yl]-N-[5-[[(2R)-4-[methyl(propan-2-yl)amino]-1-phenylsulfanylbutan-2-yl]amino]-4-nitrothiophen-2-yl]sulfonylbenzamide	KI	0.064 nM	US-9493431: Apoptosis-inducing agent for the treatment of cancer and immune and autoimmune diseases
4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-N-[5-[[(2R)-4-[methyl(propan-2-yl)amino]-1-phenylsulfanylbutan-2-yl]amino]-4-nitrothiophen-2-yl]sulfonylbenzamide	KI	0.084 nM	US-9493431: Apoptosis-inducing agent for the treatment of cancer and immune and autoimmune diseases
N-cyclopropyl-4-[6-[(3-fluoro-2-hydroxyphenyl)-hydroxymethyl]-8-(3,3,3-trifluoropropylamino)imidazo[1,2-b]pyridazin-3-yl]-2-methylbenzamide	IC50	0.2 nM	US-9512126: Substituted imidazopyridazines
N-cyclopropyl-4-[6-[1-(3-fluoro-2-hydroxyphenyl)-1-hydroxyethyl]-8-(3,3,3-trifluoropropylamino)imidazo[1,2-b]pyridazin-3-yl]-2-methylbenzamide	IC50	0.3 nM	US-9512126: Substituted imidazopyridazines
N-cyclopropyl-4-[6-[(2,5-difluorophenyl)-hydroxymethyl]-8-(3,3,3-trifluoropropylamino)imidazo[1,2-b]pyridazin-3-yl]-2-methylbenzamide	IC50	0.3 nM	US-9512126: Substituted imidazopyridazines
N-cyclopropyl-4-[6-[1-(3-fluorophenyl)ethenyl]-8-(3,3,3-trifluoropropylamino)imidazo[1,2-b]pyridazin-3-yl]-2-methylbenzamide	IC50	0.3 nM	US-9512126: Substituted imidazopyridazines
4-[4-[[2-(4-chlorophenyl)-5,5-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[5-[[(2R)-4-[methyl(propan-2-yl)amino]-1-phenylsulfanylbutan-2-yl]amino]-4-nitrothiophen-2-yl]sulfonylbenzamide	KI	0.307 nM	US-9493431: Apoptosis-inducing agent for the treatment of cancer and immune and autoimmune diseases
N-cyclopropyl-4-[6-[1-(3-fluoro-4-methoxyphenyl)ethenyl]-8-(3,3,3-trifluoropropylamino)imidazo[1,2-b]pyridazin-3-yl]-2-methylbenzamide	IC50	0.4 nM	US-9512126: Substituted imidazopyridazines
N-cyclopropyl-4-[6-[1-(2,3-difluorophenyl)ethenyl]-8-(3,3,3-trifluoropropylamino)imidazo[1,2-b]pyridazin-3-yl]-2-methylbenzamide	IC50	0.4 nM	US-9512126: Substituted imidazopyridazines
N-cyclopropyl-4-[6-[1-(5-fluoro-2-hydroxyphenyl)ethenyl]-8-(3,3,3-trifluoropropylamino)imidazo[1,2-b]pyridazin-3-yl]-2-methylbenzamide	IC50	0.4 nM	US-9512126: Substituted imidazopyridazines
N-cyclopropyl-4-[6-[1-(5-fluoro-2-hydroxyphenyl)cyclopropyl]-8-(3,3,3-trifluoropropylamino)imidazo[1,2-b]pyridazin-3-yl]-2-methylbenzamide	IC50	0.4 nM	US-9512126: Substituted imidazopyridazines
N-cyclopropyl-4-[6-(3-fluoro-4-methoxybenzoyl)-8-(3,3,3-trifluoropropylamino)imidazo[1,2-b]pyridazin-3-yl]-2-methylbenzamide	IC50	0.4 nM	US-9512126: Substituted imidazopyridazines
2-(3-chlorophenoxy)-4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)sulfonyl]benzamide	KI	0.407 nM	US-9493431: Apoptosis-inducing agent for the treatment of cancer and immune and autoimmune diseases
3-[methyl-[(8S,9S,13S,14S)-13-methyl-17-(6-methylpyridazin-4-yl)-6,7,8,9,11,12,14,15-octahydrocyclopenta[a]phenanthrene-3-carbonyl]amino]propanoic acid	IC50	0.5 nM	US-9487554: Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, processes for their preparation, pharmaceutical preparations comprising them and their use for preparing medicaments
N-cyclopropyl-4-[6-(3-methoxybenzoyl)-8-(3,3,3-trifluoropropylamino)imidazo[1,2-b]pyridazin-3-yl]-2-methylbenzamide	IC50	0.5 nM	US-9512126: Substituted imidazopyridazines
N-cyclopropyl-4-[6-[1-(4-methoxyphenyl)ethenyl]-8-(3,3,3-trifluoropropylamino)imidazo[1,2-b]pyridazin-3-yl]-2-methylbenzamide	IC50	0.5 nM	US-9512126: Substituted imidazopyridazines
N-cyclopropyl-4-[6-[(2,5-difluorophenyl)-difluoromethyl]-8-(3,3,3-trifluoropropylamino)imidazo[1,2-b]pyridazin-3-yl]-2-methylbenzamide	IC50	0.5 nM	US-9512126: Substituted imidazopyridazines
N-cyclopropyl-4-[6-[difluoro-(3-fluoro-4-methoxyphenyl)methyl]-8-(3,3,3-trifluoropropylamino)imidazo[1,2-b]pyridazin-3-yl]-2-methylbenzamide	IC50	0.6 nM	US-9512126: Substituted imidazopyridazines
N-cyclopropyl-4-[6-(2,5-difluorobenzoyl)-8-(3,3,3-trifluoropropylamino)imidazo[1,2-b]pyridazin-3-yl]-2-methylbenzamide	IC50	0.6 nM	US-9512126: Substituted imidazopyridazines
N-cyclopropyl-4-[6-(2,3-difluorobenzoyl)-8-(3,3,3-trifluoropropylamino)imidazo[1,2-b]pyridazin-3-yl]-2-methylbenzamide	IC50	0.6 nM	US-9512126: Substituted imidazopyridazines
N-cyclopropyl-4-[6-[1-(2,5-difluorophenyl)ethenyl]-8-(3,3,3-trifluoropropylamino)imidazo[1,2-b]pyridazin-3-yl]-2-methylbenzamide	IC50	0.6 nM	US-9512126: Substituted imidazopyridazines
N-cyclopropyl-4-[6-[difluoro-(4-methoxyphenyl)methyl]-8-(3,3,3-trifluoropropylamino)imidazo[1,2-b]pyridazin-3-yl]-2-methylbenzamide	IC50	0.6 nM	US-9512126: Substituted imidazopyridazines
4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-2-(1H-indol-5-yloxy)-N-[4-nitro-5-(3-pyrrolidin-1-ylpropylamino)thiophen-2-yl]sulfonylbenzamide	KI	0.649 nM	US-9493431: Apoptosis-inducing agent for the treatment of cancer and immune and autoimmune diseases
N-cyclopropyl-4-[6-[fluoro-(3-fluorophenyl)methyl]-8-(3,3,3-trifluoropropylamino)imidazo[1,2-b]pyridazin-3-yl]-2-methylbenzamide	IC50	0.7 nM	US-9512126: Substituted imidazopyridazines
N-cyclopropyl-4-[6-[difluoro-(3-fluorophenyl)methyl]-8-(3,3,3-trifluoropropylamino)imidazo[1,2-b]pyridazin-3-yl]-2-methylbenzamide	IC50	0.7 nM	US-9512126: Substituted imidazopyridazines
N-cyclopropyl-4-[6-[1-(2,3-difluorophenyl)cyclopropyl]-8-(3,3,3-trifluoropropylamino)imidazo[1,2-b]pyridazin-3-yl]-2-methylbenzamide	IC50	0.7 nM	US-9512126: Substituted imidazopyridazines
(3R)-3-[[(8S,9S,13S,14S)-17-(5-fluoro-3-pyridinyl)-13-methyl-6,7,8,9,11,12,14,15-octahydrocyclopenta[a]phenanthrene-3-carbonyl]amino]butanoic acid	IC50	0.8 nM	US-9487554: Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, processes for their preparation, pharmaceutical preparations comprising them and their use for preparing medicaments
N-cyclopropyl-4-[6-[1-(3-methoxyphenyl)ethenyl]-8-(3,3,3-trifluoropropylamino)imidazo[1,2-b]pyridazin-3-yl]-2-methylbenzamide	IC50	0.8 nM	US-9512126: Substituted imidazopyridazines
N-cyclopropyl-4-[6-[1-(2,5-difluorophenyl)cyclopropyl]-8-(3,3,3-trifluoropropylamino)imidazo[1,2-b]pyridazin-3-yl]-2-methylbenzamide	IC50	0.8 nM	US-9512126: Substituted imidazopyridazines
N-cyclopropyl-4-[6-[1-(3-fluorophenyl)cyclopropyl]-8-(3,3,3-trifluoropropylamino)imidazo[1,2-b]pyridazin-3-yl]-2-methylbenzamide	IC50	0.9 nM	US-9512126: Substituted imidazopyridazines
(1S,2R,4R)-4-hydroxy-2-methyl-4-[5-[3-(1H-pyrazol-4-yl)-5-[[4-(trifluoromethyl)pyrimidin-2-yl]amino]phenyl]-1,3-thiazol-2-yl]cyclohexane-1-carboxylic acid	IC50	0.959 nM	US-9499534: Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
1-(2-cyano-1-cyclopropylethyl)-3-(4-methylsulfinylanilino)pyrazole-4-carboxamide	IC50	1 nM	US-9493441: Acyclic cyanoethylpyrazoles as janus kinase inhibitors
1-(2-cyano-1-cyclopropylethyl)-3-[(2-methyl-1-oxo-3H-isoindol-5-yl)amino]pyrazole-4-carboxamide	IC50	1 nM	US-9493441: Acyclic cyanoethylpyrazoles as janus kinase inhibitors
1-(2-cyano-1-cyclopropylethyl)-3-[(1,1-dioxo-2,3-dihydro-1-benzothiophen-5-yl)amino]pyrazole-4-carboxamide	IC50	1 nM	US-9493441: Acyclic cyanoethylpyrazoles as janus kinase inhibitors
1-(2-cyano-1-cyclopropylethyl)-3-(4-sulfamoylanilino)pyrazole-4-carboxamide	IC50	1 nM	US-9493441: Acyclic cyanoethylpyrazoles as janus kinase inhibitors
1-(2-cyano-1-cyclopropylethyl)-3-[4-(dimethylsulfamoyl)anilino]pyrazole-4-carboxamide	IC50	1 nM	US-9493441: Acyclic cyanoethylpyrazoles as janus kinase inhibitors
2-[6-[[4-carbamoyl-1-(2-cyano-1-cyclopropylethyl)pyrazol-3-yl]amino]-3-oxo-1H-isoindol-2-yl]acetic acid	IC50	1 nM	US-9493441: Acyclic cyanoethylpyrazoles as janus kinase inhibitors
1-[(1R)-2-cyano-1-cyclopropylethyl]-3-[(1-oxo-2,3-dihydroisoindol-5-yl)amino]pyrazole-4-carboxamide	IC50	1 nM	US-9493441: Acyclic cyanoethylpyrazoles as janus kinase inhibitors
1-[(1R)-2-cyano-1-cyclopropylethyl]-3-(4-methylsulfonylanilino)pyrazole-4-carboxamide	IC50	1 nM	US-9493441: Acyclic cyanoethylpyrazoles as janus kinase inhibitors
3-[3-(4-fluoro-1-benzofuran-2-yl)imidazo[1,2-b]pyridazin-6-yl]oxycyclobutan-1-amine	IC50	1 nM	US-9499547: Amino-substituted imidazopyridazines
7-[[(3S)-3-amino-3-methylpyrrolidin-1-yl]methyl]-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine	IC50	1.1 nM	US-9475815: Substituted benzothienyl-pyrrolotriazines and uses thereof
cis-(1S,4R)-4-hydroxy-2,2-dimethyl-4-[5-[3-pyrazolidin-3-yl-5-[[4-(trifluoromethyl)pyrimidin-2-yl]amino]phenyl]-1,3-thiazol-2-yl]cyclohexane-1-carboxylic acid	IC50	1.11 nM	US-9499534: Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
(3S)-3-[[(8S,9S,13S,14S)-17-(5-fluoro-3-pyridinyl)-13-methyl-6,7,8,9,11,12,14,15-octahydrocyclopenta[a]phenanthrene-3-carbonyl]amino]butanoic acid	IC50	1.2 nM	US-9487554: Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, processes for their preparation, pharmaceutical preparations comprising them and their use for preparing medicaments
N-cyclopropyl-4-[6-(4-methoxybenzoyl)-8-(3,3,3-trifluoropropylamino)imidazo[1,2-b]pyridazin-3-yl]-2-methylbenzamide	IC50	1.2 nM	US-9512126: Substituted imidazopyridazines
4-hydroxy-4-[5-[3-methoxy-5-[[4-(trifluoromethyl)pyrimidin-2-yl]amino]phenyl]-1,3-thiazol-2-yl]cyclohexane-1-carboxylic acid	IC50	1.29 nM	US-9499534: Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
cis-(1S,4R)-4-[5-[3-(6-amino-3-pyridinyl)-5-[[4-(trifluoromethyl)pyrimidin-2-yl]amino]phenyl]-1,3-thiazol-2-yl]-4-hydroxy-2,2-dimethylcyclohexane-1-carboxylic acid	IC50	1.29 nM	US-9499534: Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
3-[[(8S,9S,13S,14S)-17-(5-fluoro-3-pyridinyl)-13-methyl-6,7,8,9,11,12,14,15-octahydrocyclopenta[a]phenanthrene-3-carbonyl]-methylamino]propanoic acid	IC50	1.3 nM	US-9487554: Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, processes for their preparation, pharmaceutical preparations comprising them and their use for preparing medicaments
4-[[[(8S,9S,13S,14S)-17-(5-fluoro-3-pyridinyl)-13-methyl-6,7,8,9,11,12,14,15-octahydrocyclopenta[a]phenanthrene-3-carbonyl]amino]methyl]oxane-4-carboxylic acid	IC50	1.4 nM	US-9487554: Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, processes for their preparation, pharmaceutical preparations comprising them and their use for preparing medicaments

ChEMBL bioactivities

125 potent at pChembl≥5 of 155 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.51	IC50	31	nM	CHEMBL379437
7.34	IC50	46.1	nM	CHEMBL209755
7.29	IC50	51.2	nM	CHEMBL4216562
7.00	IC50	100	nM	CHEMBL3360523
7.00	IC50	100	nM	CHEMBL3360520
6.92	Ki	120	nM	CHEMBL442360
6.85	IC50	142	nM	CHEMBL216505
6.80	IC50	160	nM	CHEMBL4757438
6.77	Ki	170	nM	CHEMBL4757438
6.70	IC50	200	nM	CHEMBL3360522
6.70	IC50	200	nM	CHEMBL3360504
6.68	IC50	210	nM	CHEMBL5199600
6.52	IC50	300	nM	CHEMBL3360532
6.52	IC50	300	nM	CHEMBL3360531
6.52	IC50	300	nM	CHEMBL5174343
6.51	IC50	310	nM	CHEMBL5184218
6.48	IC50	330	nM	CHEMBL4763818
6.46	IC50	350	nM	CHEMBL5169380
6.44	IC50	360	nM	CHEMBL5079695
6.40	IC50	400	nM	CHEMBL3360530
6.40	IC50	400	nM	CHEMBL3360518
6.38	IC50	420	nM	CHEMBL4777228
6.38	Ki	420	nM	CHEMBL58951
6.34	IC50	460	nM	CHEMBL4797471
6.31	Ki	490	nM	CHEMBL197460
6.30	IC50	500	nM	CHEMBL3360535
6.30	IC50	500	nM	CHEMBL3360513
6.30	IC50	500	nM	CHEMBL3360505
6.30	IC50	500	nM	ALPHA-TOCOPHEROL
6.30	IC50	500	nM	CHEMBL4794932
6.28	IC50	530	nM	CHEMBL4748062
6.27	IC50	540	nM	CHEMBL4764480
6.22	IC50	600	nM	CHEMBL3360529
6.22	IC50	600	nM	CHEMBL3360512
6.22	IC50	600	nM	CHEMBL2430537
6.22	IC50	600	nM	CHEMBL565458
6.21	IC50	624	nM	CHEMBL211916
6.18	Ki	660	nM	CHEMBL195934
6.17	IC50	680	nM	CHEMBL5400371
6.16	IC50	700	nM	CHEMBL3360521
6.16	IC50	700	nM	CHEMBL3360519
6.16	IC50	700	nM	CHEMBL582973
6.16	IC50	700	nM	CHEMBL570107
6.15	IC50	704	nM	CHEMBL212685
6.14	IC50	730	nM	CHEMBL5088562
6.14	IC50	730	nM	CHEMBL5081631
6.10	IC50	800	nM	CHEMBL3360510
6.10	IC50	800	nM	CHEMBL1234570
6.10	IC50	800	nM	CHEMBL5275770
6.07	Ki	850	nM	CHEMBL58507

PubChem BioAssay actives

127 with measured affinity, of 435 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
3-[[8-[[2-[2,3-dichloro-4-(1-hydroxy-2-methylidenebutyl)phenoxy]acetyl]amino]octanoylamino]methyl]-5-[[9-[[2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetyl]amino]nonanoylamino]methyl]benzamide	266617: Inhibition of GST P1-1	ic50	0.0310	uM
3-[[6-[[2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetyl]amino]hexanoylamino]methyl]-5-[[6-[[2-[2,3-dichloro-4-(2-methylprop-2-enoyl)phenoxy]acetyl]amino]hexanoylamino]methyl]benzamide	266617: Inhibition of GST P1-1	ic50	0.0461	uM
[6’-acetyloxy-5-(chloromethyl)-3-oxospiro[2-benzofuran-1,9’-xanthene]-3’-yl] acetate	1384572: Inhibition of human GSTP1-1 expressed in HEK293 cells by by CDNB-GSH conjugation assay	ic50	0.0512	uM
3-[4-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]phenyl]-N-phenylmethoxypropanamide	1174247: Inhibition of GSTP1-1 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.1000	uM
N-methoxy-4-[2-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]ethyl]benzamide	1174247: Inhibition of GSTP1-1 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.1000	uM
2-amino-5-[[1-[[carboxy(phenyl)methyl]amino]-3-[(4-chlorophenyl)methylsulfanyl]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid	75277: Inhibitory activity was measured on recombinant human Glutathione S-transferase P	ki	0.1200	uM
3-[[4-[4-[4-[[2-(4-but-1-en-2-yl-2,3-dichlorophenoxy)acetyl]amino]butanoylamino]butanoylamino]butanoylamino]methyl]-5-[[4-[4-[4-[[2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetyl]amino]butanoylamino]butanoylamino]butanoylamino]methyl]benzamide	266617: Inhibition of GST P1-1	ic50	0.1420	uM
6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]hexyl 4-[3-(dimethylamino)propylamino]-4-oxobutanoate	1731076: Inhibition of GSTP1-1 (unknown origin) using reduced GSH and CDNB as substrate incubated for 10 mins followed by substrate addition by microplate reader analysis	ic50	0.1600	uM
7-nitro-4-(2-phenylethylsulfanyl)-2,1,3-benzoxadiazole	1174247: Inhibition of GSTP1-1 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.2000	uM
4-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanylmethyl]-N-phenylmethoxybenzamide	1174247: Inhibition of GSTP1-1 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.2000	uM
(26,28-dihydroxy-17-phosphonocarbonyl-25,27-dipropoxypentacyclo[19.3.1.13,7.19,13.115,19]octacosa-1(25),3,5,7(28),9(27),10,12,15(26),16,18,21,23-dodecaene-5-carbonyl)phosphonic acid	1896237: Inhibition of recombinant human GSTP1-1 using GSH and CDNB as substrate preincubated for 2 mins followed by substrate addition and measured upto 6 mins in the presence of UV irradiation by spectrophotometric analysis	ic50	0.2100	uM
4-(cyclohexylmethylsulfanyl)-7-nitro-2,1,3-benzoxadiazole	1174247: Inhibition of GSTP1-1 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.3000	uM
4-tert-butylsulfanyl-7-nitro-2,1,3-benzoxadiazole	1174247: Inhibition of GSTP1-1 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.3000	uM
(25,27-dibutoxy-26,28-dihydroxy-17-phosphonocarbonylpentacyclo[19.3.1.13,7.19,13.115,19]octacosa-1(25),3,5,7(28),9(27),10,12,15(26),16,18,21,23-dodecaene-5-carbonyl)phosphonic acid	1896237: Inhibition of recombinant human GSTP1-1 using GSH and CDNB as substrate preincubated for 2 mins followed by substrate addition and measured upto 6 mins in the presence of UV irradiation by spectrophotometric analysis	ic50	0.3000	uM
[26,28-dihydroxy-17-[hydroxy(diphosphono)methyl]-25,27-dipropoxypentacyclo[19.3.1.13,7.19,13.115,19]octacosa-1(25),3,5,7(28),9(27),10,12,15(26),16,18,21,23-dodecaene-5-carbonyl]phosphonic acid	1896237: Inhibition of recombinant human GSTP1-1 using GSH and CDNB as substrate preincubated for 2 mins followed by substrate addition and measured upto 6 mins in the presence of UV irradiation by spectrophotometric analysis	ic50	0.3100	uM
6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]hexyl 4-morpholin-4-yl-4-oxobutanoate	1731076: Inhibition of GSTP1-1 (unknown origin) using reduced GSH and CDNB as substrate incubated for 10 mins followed by substrate addition by microplate reader analysis	ic50	0.3300	uM
(26,28-dihydroxy-25,27-dioctoxy-17-phosphonocarbonylpentacyclo[19.3.1.13,7.19,13.115,19]octacosa-1(25),3,5,7(28),9(27),10,12,15(26),16,18,21,23-dodecaene-5-carbonyl)phosphonic acid	1896237: Inhibition of recombinant human GSTP1-1 using GSH and CDNB as substrate preincubated for 2 mins followed by substrate addition and measured upto 6 mins in the presence of UV irradiation by spectrophotometric analysis	ic50	0.3500	uM
2-naphthalen-2-ylcycloprop-2-en-1-one	1830591: Inhibition of recombinant GSTP1 (unknown origin) using GSH substrate	ic50	0.3600	uM
2-[4-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]phenyl]acetic acid	1174247: Inhibition of GSTP1-1 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.4000	uM
methyl 3-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]-2-(phenylmethoxycarbonylamino)propanoate	1174247: Inhibition of GSTP1-1 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.4000	uM
6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]hexyl 4-(4-methoxyanilino)-4-oxobutanoate	1731076: Inhibition of GSTP1-1 (unknown origin) using reduced GSH and CDNB as substrate incubated for 10 mins followed by substrate addition by microplate reader analysis	ic50	0.4200	uM
2-amino-5-[[3-benzylsulfanyl-1-[[carboxy(phenyl)methyl]amino]-1-oxopropan-2-yl]amino]-5-oxopentanoic acid	75277: Inhibitory activity was measured on recombinant human Glutathione S-transferase P	ki	0.4200	uM
6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]hexyl 4-oxo-4-(2-pyrrolidin-1-ylethylamino)butanoate	1731076: Inhibition of GSTP1-1 (unknown origin) using reduced GSH and CDNB as substrate incubated for 10 mins followed by substrate addition by microplate reader analysis	ic50	0.4600	uM
2-amino-5-[[1-(carboxymethylamino)-3-(2-hydroxy-2-phenylethyl)sulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid	254445: Inhibition constant against glutathione S-transferase pi using GSH (0.1-3mM), 1 mM 1-chloro-2,4-dinitrobenzene	ki	0.4900	uM
7-nitro-4-(3-phenylpropylsulfanyl)-2,1,3-benzoxadiazole	1174247: Inhibition of GSTP1-1 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.5000	uM
N-methoxy-4-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]benzamide	1174247: Inhibition of GSTP1-1 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.5000	uM
8-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]octan-1-ol	1174247: Inhibition of GSTP1-1 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.5000	uM
(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-ol	1384566: Inhibition of human GSTP1-1	ic50	0.5000	uM
6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]hexyl 4-oxo-4-piperidin-1-ylbutanoate	1731076: Inhibition of GSTP1-1 (unknown origin) using reduced GSH and CDNB as substrate incubated for 10 mins followed by substrate addition by microplate reader analysis	ic50	0.5000	uM
4-[6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]hexoxy]-4-oxobutanoic acid	1731076: Inhibition of GSTP1-1 (unknown origin) using reduced GSH and CDNB as substrate incubated for 10 mins followed by substrate addition by microplate reader analysis	ic50	0.5300	uM
6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]hexyl 4-[2-(dimethylamino)ethylamino]-4-oxobutanoate	1731076: Inhibition of GSTP1-1 (unknown origin) using reduced GSH and CDNB as substrate incubated for 10 mins followed by substrate addition by microplate reader analysis	ic50	0.5400	uM
N,N-dimethyl-4-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]benzamide	1174247: Inhibition of GSTP1-1 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.6000	uM
methyl 2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]propanoate	1174247: Inhibition of GSTP1-1 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.6000	uM
1-[2-chloro-4-[(3-phenyl-1,2,4-oxadiazol-5-yl)methoxy]phenyl]-2-methylprop-2-en-1-one	441756: Inhibition of GST P1-1 in human HL60 cell lysate	ic50	0.6000	uM
7-nitro-4-phenylsulfanyl-2,1,3-benzoxadiazole	1174247: Inhibition of GSTP1-1 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.6000	uM
3-[[4-[[2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetyl]amino]butanoylamino]methyl]-5-[[4-[[2-[2,3-dichloro-4-(2-methylprop-2-enoyl)phenoxy]acetyl]amino]butanoylamino]methyl]benzamide	266617: Inhibition of GST P1-1	ic50	0.6240	uM
2-amino-5-[[1-(carboxymethylamino)-3-[carboxy(phenyl)methyl]sulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid	254445: Inhibition constant against glutathione S-transferase pi using GSH (0.1-3mM), 1 mM 1-chloro-2,4-dinitrobenzene	ki	0.6600	uM
N-[3-[5-chloro-2-[2-methoxy-4-(4-pent-4-ynoylpiperazin-1-yl)anilino]pyrimidin-4-yl]oxyphenyl]-5-(3-oxocyclopropen-1-yl)pentanamide	2028368: Inhibition of recombinant GSTP1 (unknown origin) using GSH as substrate incubated for 5 mins by absorbance based analysis	ic50	0.6800	uM
3-[4-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]phenyl]propanoic acid	1174247: Inhibition of GSTP1-1 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.7000	uM
ethyl 4-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanylmethyl]benzoate	1174247: Inhibition of GSTP1-1 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.7000	uM
1-[2-chloro-4-[[3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl]methoxy]phenyl]-2-methylprop-2-en-1-one	441756: Inhibition of GST P1-1 in human HL60 cell lysate	ic50	0.7000	uM
1-[2-chloro-4-[[3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl]methoxy]phenyl]-2-methylprop-2-en-1-one	441756: Inhibition of GST P1-1 in human HL60 cell lysate	ic50	0.7000	uM
3,5-bis[[[2-[[2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetyl]amino]acetyl]amino]methyl]benzamide	266617: Inhibition of GST P1-1	ic50	0.7040	uM
2-(4-phenoxyphenyl)cycloprop-2-en-1-one	1830591: Inhibition of recombinant GSTP1 (unknown origin) using GSH substrate	ic50	0.7300	uM
2-(4-phenylmethoxyphenyl)cycloprop-2-en-1-one	1830591: Inhibition of recombinant GSTP1 (unknown origin) using GSH substrate	ic50	0.7300	uM
4-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]benzamide	1174247: Inhibition of GSTP1-1 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.8000	uM
6-[(4-nitro-6,7-dihydro-2,1,3-benzoxadiazol-7-yl)sulfanyl]hexan-1-ol	1933414: Inhibition of human GSTP1-1 expressed in Escherichia coli assessed as inhibition by fluorescence based analysis	ic50	0.8000	uM
6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)sulfanyl]hexan-1-ol	1174247: Inhibition of GSTP1-1 (unknown origin) using GSH substrate by spectrophotometric method	ic50	0.8000	uM
2-amino-5-[[1-[[carboxy(phenyl)methyl]amino]-3-hexylsulfanyl-1-oxopropan-2-yl]amino]-5-oxopentanoic acid	75277: Inhibitory activity was measured on recombinant human Glutathione S-transferase P	ki	0.8500	uM
3,5-bis[[[2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetyl]amino]methyl]benzamide	266617: Inhibition of GST P1-1	ic50	0.9924	uM

CTD chemical–gene interactions

388 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Glutathione	increases activity, affects binding, increases reaction, increases abundance, increases hydroxylation (+6 more)	15
Doxorubicin	increases expression, decreases reaction, affects binding, increases reaction, affects cotreatment (+3 more)	13
Cisplatin	affects response to substance, increases response to substance, increases metabolic processing, increases phosphorylation, affects cotreatment (+3 more)	11
Ethacrynic Acid	affects cotreatment, increases cleavage, increases reaction, affects metabolic processing, decreases response to substance (+5 more)	11
Curcumin	increases expression, increases reaction, decreases expression, affects binding, decreases activity (+4 more)	8
Benzo(a)pyrene	decreases response to substance, affects activity, affects metabolic processing, decreases methylation, increases expression (+1 more)	7
Tobacco Smoke Pollution	decreases expression, increases expression, increases metabolic processing, increases response to substance, affects expression	7
Decitabine	increases expression, increases reaction, affects cotreatment, decreases methylation, decreases reaction	6
Air Pollutants	affects response to substance, increases abundance, increases response to substance	6
Hydrogen Peroxide	decreases response to substance, increases degradation, affects localization, decreases expression, increases expression	6
Ozone	affects response to substance, affects reaction, increases reaction, increases response to substance	6
Pesticides	affects response to substance	6
Valproic Acid	increases expression, affects cotreatment	6
Particulate Matter	affects response to substance, increases abundance, increases response to substance, increases expression	6
sodium arsenite	decreases reaction, increases methylation, decreases response to substance, increases expression, decreases expression	5
Oxaliplatin	decreases activity, decreases response to substance, increases expression, affects cotreatment, affects response to substance	5
Polycyclic Aromatic Hydrocarbons	affects metabolic processing, decreases activity, increases metabolic processing, increases response to substance, affects response to substance	5
benzyl isothiocyanate	affects binding, decreases activity, increases expression, affects metabolic processing	4
Resveratrol	affects cotreatment, increases expression	4
Arsenic	affects metabolic processing, increases expression, affects response to substance, affects abundance	4
Vehicle Emissions	affects methylation, affects response to substance, increases response to substance, increases abundance	4
Benzene	increases expression, affects response to substance, affects metabolic processing, increases metabolic processing	4
Dinitrochlorobenzene	decreases response to substance, affects binding, increases glutathionylation, decreases reaction, increases activity (+1 more)	4
Fluorouracil	decreases expression, increases expression, affects response to substance, decreases response to substance, affects cotreatment	4
Thiotepa	increases metabolic processing, affects metabolic processing, affects reaction, affects response to substance, decreases response to substance (+2 more)	4
Styrene	increases reaction, increases response to substance, affects response to substance, increases mutagenesis	4
methylmercuric chloride	decreases response to substance, affects binding, decreases reaction, increases glutathionylation, increases expression (+1 more)	3
bisphenol A	decreases expression, decreases methylation, increases methylation	3
sulforaphane	affects metabolic processing, affects binding, decreases activity	3
4-hydroxy-2-nonenal	affects binding, decreases activity, decreases response to substance	3

ChEMBL screening assays

126 unique, capped per target: 107 binding, 19 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1033242	Binding	Specific activity of human Glutathione S-transferase P at 50 uM by spectrophotometric analysis in presence of glutathione	Synthesis, mechanistic studies, and anti-proliferative activity of glutathione/glutathione S-transferase-activated nitric oxide prodrugs. — Bioorg Med Chem
CHEMBL1743234	ADMET	Substrates for human cytosolic glutathione transferase GSTP1	Casarett and Doull’s Toxicology The Basic Science of Poisons, 7th edition

Cellosaurus cell lines

9 cell lines: 5 cancer cell line, 3 spontaneously immortalized cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D1WP	Abcam A-549 GSTP1 KO	Cancer cell line	Male
CVCL_D2B2	Abcam HCT 116 GSTP1 KO	Cancer cell line	Male
CVCL_D2NH	Abcam THP-1 GSTP1 KO	Cancer cell line	Male
CVCL_D9G1	Ubigene HEK293 GSTP1 KO	Transformed cell line	Female
CVCL_F0F8	V79MZh1A1/hGSTP1-23	Spontaneously immortalized cell line	Male
CVCL_F0F9	V79MZh1A1/hGSTP1-25	Spontaneously immortalized cell line	Male
CVCL_F0FA	V79MZr1A1/hGSTP1-33	Spontaneously immortalized cell line	Male
CVCL_SQ71	HAP1 GSTP1 (-)	Cancer cell line	Male
CVCL_UG45	HeLa/GSTP1	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.